Faecal Calprotectin in Assessment of Mucosal Healing in Adults with Inflammatory Bowel Disease: A Meta-Analysis
Open accessThe DOI matches its Crossref record; 85 of the 86 references it cites were found in a registry or an index.
Abstract
Achieving mucosal healing in patients with inflammatory bowel disease is related to a higher incidence of sustained clinical remission and it translates to lower rates of hospitalisation and surgery. The assessment methods of disease activity and response to therapy are limited and mainly rely on colonoscopy. This meta-analysis reviews the effectiveness of using faecal calprotectin as a marker for mucosal healing in inflammatory bowel disease. Two meta-analyses were conducted in parallel. The analysis on the use of faecal calprotectin in monitoring mucosal healing in colonic Crohn’s disease is based on 16 publications (17 studies). The data set for diagnostic values of faecal calprotectin in ulcerative colitis is composed of 35 original publications (total 49 studies). The DOR for the use of faecal calprotectin in Crohn’s disease is estimated to be 11.20 and the area under the sROCis 0.829. In cases of ulcerative colitis, the DOR is 14.48, while the AUC sROC is 0.858. Heterogeneity of the studies was moderatetosubstantial. Collected data show overall good sensitivity and specificity of the faecal calprotectin test, as well as a good DOR. Thus, monitoring of mucosal healing with a non-invasive faecal calprotectin test may represent an attractive option for physicians and patients with inflammatory bowel disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is an established, sensitive marker used to monitor IBD activity and, by extension, reflects microbiota-driven mucosal inflammation.119,121,122”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [121]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050516 · Cited by 3,902 · cited 7×
“Authors collected data from hundreds of UC patients participating in a phase 4 trial and performed a post-hoc analysis with two MH definitions (MES = 0, MES ≤ 1).”
MethodInfluentialReitsma, J. B., Glas, A. S., Rutjes, A. W. S., Scholten, R. J. P. M., Bossuyt, P. M., & Zwinderman, A. H. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.02.022 · Cited by 3,369 · cited 1×
“The univariate effects model predicts the DOR to be higher than that estimated with the use of the bivariate model based on the Reitsma’s method [77].”
MethodCoated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis
Schroeder, K. W., Tremaine, W. J., & Ilstrup, D. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198712243172603 · Cited by 3,026 · cited 7×
“Authors collected data from hundreds of UC patients participating in a phase 4 trial and performed a post-hoc analysis with two MH definitions (MES = 0, MES ≤ 1).”
MethodInfluentialMagro, F., Gionchetti, P., Eliakim, R., Ardizzone, S., Armuzzi, A., Barreiro-de Acosta, M., Burisch, J., Gecse, K. B., Hart, A. L., Hindryckx, P., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx008 · Cited by 1,910 · cited 1×
“The concept of deep remission (DR) is complex, and a standardised definition of DR is still missing [6].”
BackgroundPeyrin-Biroulet, L., Sandborn, W., Sands, B. E., Reinisch, W., Bemelman, W., Bryant, R. V., D'Haens, G., Dotan, I., Dubinsky, M., Feagan, B., et al. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.233 · Cited by 1,844 · cited 1×
“In addition, for CD, the resolution of inflammation-related findings on imaging in patients who cannot be adequately assessed with ileocolonoscopy [4,5].”
BackgroundMaaser, C., Sturm, A., Vavricka, S. R., Kucharzik, T., Fiorino, G., Annese, V., Calabrese, E., Baumgart, D. C., Bettenworth, D., Borralho Nunes, P., et al. (2019) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjy113 · Cited by 1,823
Daperno, M., D'Haens, G., Van Assche, G., Baert, F., Bulois, P., Maunoury, V., Sostegni, R., Rocca, R., Pera, A., Gevers, A., et al. (2004) · Gastrointestinal Endoscopy · doi:10.1016/s0016-5107(04)01878-4 · Cited by 1,774 · cited 8×
“This could be explained by the fact that SES-CD is a simplified, easier to calculate version of CDEIS.”
MethodInfluentialSeverity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis
Rutter, M., Saunders, B., Wilkinson, K., Rumbles, S., Schofield, G., Kamm, M., Williams, C., Price, A., Talbot, I., & Forbes, A. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.11.010 · Cited by 1,255
Mucosal Healing in Inflammatory Bowel Disease: Results From a Norwegian Population-Based Cohort
Frøslie, K. F., Jahnsen, J., Moum, B. A., & Vatn, M. H. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.051 · Cited by 1,121
Colombel, J. F., Rutgeerts, P., Reinisch, W., Esser, D., Wang, Y., Lang, Y., Marano, C. W., Strauss, R., Oddens, B. J., Feagan, B. G., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.054 · Cited by 919
Extraintestinal Manifestations of Inflammatory Bowel Disease
Vavricka, S. R., Schoepfer, A., Scharl, M., Lakatos, P. L., Navarini, A., & Rogler, G. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000392 · Cited by 909
European evidence based consensus for endoscopy in inflammatory bowel disease
Annese, V., Daperno, M., Rutter, M. D., Amiot, A., Bossuyt, P., East, J., Ferrante, M., Götz, M., Katsanos, K. H., Kießlich, R., et al. (2013) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2013.09.016 · Cited by 815 · cited 5×
“This could be explained by the fact that SES-CD is a simplified, easier to calculate version of CDEIS.”
MethodInfluentialEvidence-based clinical practice guidelines for inflammatory bowel disease
Matsuoka, K., Kobayashi, T., Ueno, F., Matsui, T., Hirai, F., Inoue, N., Kato, J., Kobayashi, K., Kobayashi, K., Koganei, K., et al. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-018-1439-1 · Cited by 698
The epidemiology of inflammatory bowel disease: East meets west
Mak, W. Y., Zhao, M., Ng, S. C., & Burisch, J. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14872 · Cited by 631 · cited 1×
“The urgent requirement for non-invasive indices in IBD is additionally augmented by the recent global growth in IBD incidence rates [24].”
BackgroundSturm, A., Maaser, C., Calabrese, E., Annese, V., Fiorino, G., Kucharzik, T., Vavricka, S. R., Verstockt, B., van Rheenen, P., Tolan, D., et al. (2019) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjy114 · Cited by 461
Reliability and Initial Validation of the Ulcerative Colitis Endoscopic Index of Severity
Travis, S. P. L., Schnell, D., Krzeski, P., Abreu, M. T., Altman, D. G., Colombel, J., Feagan, B. G., Hanauer, S. B., Lichtenstein, G. R., Marteau, P. R., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.07.024 · Cited by 457
Rutter, M. D., Saunders, B. P., Wilkinson, K. H., Rumbles, S., Schofield, G., Kamm, M. A., Williams, C. B., Price, A. B., Talbot, I. C., & Forbes, A. (2004) · Gut · doi:10.1136/gut.2003.038505 · Cited by 442
Shah, S. C., Colombel, J. ‐., Sands, B. E., & Narula, N. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13475 · Cited by 357
Schoepfer, A. M., Beglinger, C., Straumann, A., Safroneeva, E., Romero, Y., Armstrong, D., Schmidt, C., Trummler, M., Pittet, V., & Vavricka, S. R. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e3182810066 · Cited by 294
Ardizzone, S., Cassinotti, A., Duca, P., Mazzali, C., Penati, C., Manes, G., Marmo, R., Massari, A., Molteni, P., Maconi, G., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.12.028 · Cited by 283
Colombel, J.-F., D’haens, G., Lee, W.-J., Petersson, J., & Panaccione, R. (2020) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjz131 · Cited by 283 · cited 1×
“In addition, for CD, the resolution of inflammation-related findings on imaging in patients who cannot be adequately assessed with ileocolonoscopy [4,5].”
BackgroundMechanism of extracellular release of human neutrophil calprotectin complex
Voganatsi, A., Panyutich, A., Miyasaki, K. T., & Murthy, R. K. (2001) · Journal of Leukocyte Biology · doi:10.1189/jlb.70.1.130 · Cited by 173 · cited 1×
“The release of calprotectin is most likely related with death of neutrophils at the site of inflammation [29].”
BackgroundLobatón, T., López‐García, A., Rodríguez‐Moranta, F., Ruiz, A., Rodríguez, L., & Guardiola, J. (2013) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2013.05.005 · Cited by 170
Zittan, E., Kelly, O. B., Kirsch, R., Milgrom, R., Burns, J., Nguyen, G. C., Croitoru, K., Van Assche, G., Silverberg, M. S., & Steinhart, A. H. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000652 · Cited by 167
Theede, K., Holck, S., Ibsen, P. H., Ladelund, S., Nordgaard-Lassen, I., & Nielsen, A. M. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.05.038 · Cited by 164 · cited 1×
“Other MH definitions used were the modified Baron Score (mBS = 0, mBS ≤ 1), the modified PICaSSO ≤ 3 [42], the Rachmilewitz Index (RI ≤ 1 [74], RI ≤ 2 [44], RI ≤ 4 [75]); the Simple Endoscopic Score for Ulcerative Colitis (SES-UC ≤ 3 [64]), and the Ulcerative Colitis Endoscopic Index of Severity (UCEIS = 0 [63], UCEIS…”
Methodaf Björkesten, C.-G., Nieminen, U., Turunen, U., Arkkila, P., Sipponen, T., & Färkkilä, M. (2012) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2012.660542 · Cited by 153
Falvey, J. D., Hoskin, T., Meijer, B., Ashcroft, A., Walmsley, R., Day, A. S., & Gearry, R. B. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000341 · Cited by 152
Reinink, A. R., Lee, T. C., & Higgins, P. D. R. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000816 · Cited by 126
Lobatón, T., Rodríguez‐Moranta, F., Lopez, A., Sánchez, E., Alonso, L. R., & Guardiola, J. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e3182802b6e · Cited by 125
Takashima, S., Kato, J., Hiraoka, S., Nakarai, A., Takei, D., Inokuchi, T., Sugihara, Y., Takahara, M., Harada, K., Okada, H., et al. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.66 · Cited by 117
Nancey, S., Boschetti, G., Moussata, D., Cotte, E., Peyras, J., Cuerq, C., Haybrard, J., Charlois, A.-L., Mialon, A., Chauvenet, M., et al. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e3182807577 · Cited by 104
Inflammatory Bowel Disease 2017: Innovations and Changing Paradigms
Colombel, J., & Mahadevan, U. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.12.004 · Cited by 98
Κώστας, Α., Siakavellas, S. I., Kosmidis, C., Takou, A., Nikou, J., Maropoulos, G., Vlachogiannakos, J., Papatheodoridis, G., Papaconstantinou, I. G., & Bamias, G. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i41.7387 · Cited by 88
Langhorst, J., Boone, J. H., Lauche, R., Rueffer, A., & Dobos, G. (2016) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjw044 · Cited by 85 · cited 1×
“Other MH definitions used were the modified Baron Score (mBS = 0, mBS ≤ 1), the modified PICaSSO ≤ 3 [42], the Rachmilewitz Index (RI ≤ 1 [74], RI ≤ 2 [44], RI ≤ 4 [75]); the Simple Endoscopic Score for Ulcerative Colitis (SES-UC ≤ 3 [64]), and the Ulcerative Colitis Endoscopic Index of Severity (UCEIS = 0 [63], UCEIS…”
MethodFecal Calprotectin Levels Predict Histological Healing in Ulcerative Colitis
Patel, A., Panchal, H., & Dubinsky, M. C. (2017) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000001157 · Cited by 83
Walsh, A., Kormilitzin, A., Hinds, C., Sexton, V., Brain, O., Keshav, S., Uhlig, H., Geddes, J., Goodwin, G., Peters, M., et al. (2019) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjy184 · Cited by 77 · cited 1×
“Other MH definitions used were the modified Baron Score (mBS = 0, mBS ≤ 1), the modified PICaSSO ≤ 3 [42], the Rachmilewitz Index (RI ≤ 1 [74], RI ≤ 2 [44], RI ≤ 4 [75]); the Simple Endoscopic Score for Ulcerative Colitis (SES-UC ≤ 3 [64]), and the Ulcerative Colitis Endoscopic Index of Severity (UCEIS = 0 [63], UCEIS…”
MethodBiochemical Biomarkers of Mucosal Healing for Inflammatory Bowel Disease in Adults
Krzystek‐Korpacka, M., Kempiński, R., Bromke, M. A., & Neubauer, K. (2020) · Diagnostics · doi:10.3390/diagnostics10060367 · Cited by 76 · cited 1×
“From among numerous potential biomarkers which have been evaluated in IBD, only faecal calprotectin (FC) has the potential to serve as an indicator of IBD activity [28].”
BackgroundSelf-citationMak, J. W. Y., Buisson, A., Andersen, M. J., Lei, D. K., Pekow, J. R., Cohen, R. D., Kahn, S. A., Pereira, B., & Rubin, D. T. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-4980-0 · Cited by 76
Fecal Calprotectin Is Not Affected by Pregnancy
Julsgaard, M., Hvas, C. L., Gearry, R. B., Vestergaard, T., Fallingborg, J., Svenningsen, L., Kjeldsen, J., Sparrow, M., Wildt, S., Kelsen, J., et al. (2017) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000001136 · Cited by 70 · cited 2×
“suggested the use of FC in the monitoring of IBD during pregnancy [82].”
BackgroundMethodLee, S.-H., Kim, M.-J., Chang, K., Song, E. M., Hwang, S. W., Park, S. H., Yang, D., Kim, K., Byeon, J., Myung, S., et al. (2017) · BMC Gastroenterology · doi:10.1186/s12876-017-0669-7 · Cited by 65
Inokuchi, T., Kato, J., Hiraoka, S., Takashima, S., Nakarai, A., Takei, D., Sugihara, Y., Takahara, M., Kawano, S., Harada, K., et al. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000728 · Cited by 65
Lundgren, D., Eklöf, V., Palmqvist, R., Hultdin, J., & Karling, P. (2019) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2019.1566493 · Cited by 63 · cited 1×
“observed that among patients with a normal colonoscopy, FC above 50 μg/g was shown for 55% patients using acetylsalicylic acid, 24% using non-steroidal anti-inflammatory drugs, and 52% treated with proton pump inhibitors [81].”
MethodHart, L., Chavannes, M., Kherad, O., Maedler, C., Mourad, N., Marcus, V., Afif, W., Bitton, A., Lakatos, P. L., Brassard, P., et al. (2019) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjz107 · Cited by 63 · cited 1×
“[69], and all application studies contained in the publication of Stevens et al.”
BackgroundMeucci, G., Renata D'Incà, Maieron, R., Orzes, N., Vecchi, M., Visentini, D., Minoli, G., Pont, E. D., Zilli, M., Benedetti, E., et al. (2009) · Digestive and Liver Disease · doi:10.1016/j.dld.2009.07.002 · Cited by 59 · cited 2×
“Moreover, faecal calprotectin above 50 μg/g has been found in 85% of patients with colonic cancer, 81% of those with “inflammatory conditions” (active CD or in remission, active UC, ischaemic colon), and 50% of those with UC in remission [80].”
BackgroundResultYamaguchi, S., Takeuchi, Y., Arai, K., Fukuda, K., Kuroki, Y., Asonuma, K., Takahashi, H., Saruta, M., & Yoshida, H. (2016) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13061 · Cited by 58 · cited 1×
“[65], did the estimated DOR’s lower boundary of the 95% confidence interval drop below 1 (Figure 3).”
BackgroundBertani, L., Blandizzi, C., Mumolo, M. G., Ceccarelli, L., Albano, E., Tapete, G., Svizzero, G. B., Zanzi, F., Coppini, F., de Bortoli, N., et al. (2020) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000174 · Cited by 58
Kristensen, V., Klepp, P., Cvancarova, M., Roseth, A., Skar, V., & Moum, B. (2015) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jju015 · Cited by 56
Occhipinti, V., & Pastorelli, L. (2020) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izaa084 · Cited by 53
Lin, W.-C., Wong, J.-M., Tung, C.-C., Lin, C.-P., Chou, J.-W., Wang, H.-Y., Shieh, M.-J., Chang, C.-H., Liu, H.-H., & Wei, S.-C. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i48.13566 · Cited by 48 · cited 2×
“Other MH definitions used were the modified Baron Score (mBS = 0, mBS ≤ 1), the modified PICaSSO ≤ 3 [42], the Rachmilewitz Index (RI ≤ 1 [74], RI ≤ 2 [44], RI ≤ 4 [75]); the Simple Endoscopic Score for Ulcerative Colitis (SES-UC ≤ 3 [64]), and the Ulcerative Colitis Endoscopic Index of Severity (UCEIS = 0 [63], UCEIS…”
MethodChen, J.-M., Liu, T., Gao, S., Tong, X.-D., Deng, F., & Nie, B. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i46.8235 · Cited by 48 · cited 1×
“In one study it was defined as MES ≤ 2 [46].”
Mancina, R. M., Pagnotta, R., Pagliuso, C., Albi, V., Bruno, D., Garieri, P., Doldo, P., & Spagnuolo, R. (2020) · Medicina · doi:10.3390/medicina56010045 · Cited by 45 · cited 1×
“Successful control of intestinal inflammation may lead to improvement of extraintestinal manifestations of IBD, such as peripheral arthralgia [22], as well as relief in IBD-concomitant anxiety, depression, fatigue, and sleep disturbances [23].”
BackgroundThe usefulness of fecal calprotectin in assessing inflammatory bowel disease activity
Lee, Y. W., Lee, K., Lee, J. M., Chung, Y. Y., Kim, D. B., Kim, Y. J., Chung, W. C., & Paik, C. N. (2018) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.324 · Cited by 44
Stevens, T. W., Gecse, K. B., Turner, J. R., Hertogh, G. D., Rubin, D. T., & D’Haens, G. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.08.019 · Cited by 43 · cited 1×
“[62], all four individual test DOR values were rather low (between 4.”
BackgroundReinisch, W., Panaccione, R., Bossuyt, P. J., Baert, F., Armuzzi, A., Hébuterne, X., Travis, S. P. L., Danese, S., Sandborn, W. J., Schreiber, S., et al. (2020) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izaa025 · Cited by 40
Sandborn, W. J., Colombel, J., Panaccione, R., Dulai, P. S., Rosario, M., Cao, C., Barocas, M., & Lasch, K. L. (2018) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjy149 · Cited by 39 · cited 1×
“Deep remission in UC refers to complete disease quiescence regarding endoscopic activity, rectal bleeding, and bowel movement [7].”
BackgroundJusué, V., Chaparro, M., & Gisbert, J. P. (2017) · Digestive and Liver Disease · doi:10.1016/j.dld.2017.12.022 · Cited by 38 · cited 2×
“[38] with a High Range test kit, Lobatón et al.”
MethodJha, A. K., Chaudhary, M., Dayal, V. M., Kumar, A., Jha, S., Jha, P., Purkayastha, S., & Ranjan, R. (2018) · JGH Open · doi:10.1002/jgh3.12074 · Cited by 37
Cannatelli, R., Bazarova, A., Zardo, D., Nardone, O. M., Shivaji, U. N., Smith, S. C. L., Gkoutos, G. V., Ricci, C., Gui, X. S., Ghosh, S. K., et al. (2020) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izaa163 · Cited by 37 · cited 1×
“Other MH definitions used were the modified Baron Score (mBS = 0, mBS ≤ 1), the modified PICaSSO ≤ 3 [42], the Rachmilewitz Index (RI ≤ 1 [74], RI ≤ 2 [44], RI ≤ 4 [75]); the Simple Endoscopic Score for Ulcerative Colitis (SES-UC ≤ 3 [64]), and the Ulcerative Colitis Endoscopic Index of Severity (UCEIS = 0 [63], UCEIS…”
MethodNaess‐Andresen, C. F., Egelandsdal, B., & Fagerhol, M. K. (1995) · Molecular Pathology · doi:10.1136/mp.48.5.m278 · Cited by 36 · cited 1×
“Faecal calprotectin is stable for 4–7 days [30] and the sampling does not involve uncomfortable procedures.”
BackgroundÖnal, İ. K., Beyazıt, Y., Şener, B., SAVUK, B., Etik, D. Ö., Sayılır, A., Öztaş, E., Torun, S., Özın, Y., Demirel, B., et al. (2012) · The Turkish Journal of Gastroenterology · doi:10.4318/tjg.2012.0421 · Cited by 33 · cited 1×
“Other MH definitions used were the modified Baron Score (mBS = 0, mBS ≤ 1), the modified PICaSSO ≤ 3 [42], the Rachmilewitz Index (RI ≤ 1 [74], RI ≤ 2 [44], RI ≤ 4 [75]); the Simple Endoscopic Score for Ulcerative Colitis (SES-UC ≤ 3 [64]), and the Ulcerative Colitis Endoscopic Index of Severity (UCEIS = 0 [63], UCEIS…”
MethodMonitoring Crohn’s disease activity: endoscopy, fecal markers and computed tomography enterography
Lopes, S., Andrade, P., Afonso, J., Cunha, R., Rodrigues‐Pinto, E., Ramos, I. M., Macedo, G., & Magro, F. (2018) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284818769075 · Cited by 32
The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis
Carlsen, K., Riis, L. B., Elsberg, H., Maagaard, L., Thorkilgaard, T., Sørbye, S. W., Jakobsen, C., Wewer, V., Florholmen, J., Goll, R., et al. (2018) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2018.1482956 · Cited by 32
Penna, F. G. C. E., Rosa, R. M., Cunha, P. F. S., de Souza, S. C. S., & Ferrari, M. D. L. A. (2020) · BMC Gastroenterology · doi:10.1186/s12876-020-1183-x · Cited by 31
Voiosu, T. A., Benguș, A., Dinu, R., Voiosu, A. M., Balanescu, P. C., Băicuş, C., Diculescu, M., Voiosu, R., & Mateescu, B. R. (2014) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld.2014.1121.233.thv · Cited by 30 · cited 1×
“Other MH definitions used were the modified Baron Score (mBS = 0, mBS ≤ 1), the modified PICaSSO ≤ 3 [42], the Rachmilewitz Index (RI ≤ 1 [74], RI ≤ 2 [44], RI ≤ 4 [75]); the Simple Endoscopic Score for Ulcerative Colitis (SES-UC ≤ 3 [64]), and the Ulcerative Colitis Endoscopic Index of Severity (UCEIS = 0 [63], UCEIS…”
MethodIwamoto, F., Matsuoka, K., Motobayashi, M., Takenaka, K., Kuno, T., Tanaka, K., Tsukui, Y., Kobayashi, S., Yoshida, T., Fujii, T., et al. (2018) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14310 · Cited by 28
Serum trefoil factor 3 predicts disease activity in patients with ulcerative colitis.
Nakov, R., Velikova, T. V., Nakov, V., Ianiro, G., Gerova, В., & Tankova, L. (2019) · PubMed · doi:10.26355/eurrev_201901_16893 · Cited by 27
Selected biologic markers of inflammation and activity of Crohn’s disease
Karczewski, J., Swora-Cwynar, E., Rzymski, P., Poniedziałek, B., & Adamski, Z. (2015) · Autoimmunity · doi:10.3109/08916934.2015.1016221 · Cited by 26
Clinical application of faecal calprotectin in ulcerative colitis patients
Scaioli, E., Scagliarini, M., Cardamone, C., Liverani, E., Ugolini, G., Festi, D., Bazzoli, F., & Belluzzi, A. (2015) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000461 · Cited by 25
Schaffer, T., Schoepfer, A. M., Seibold, F., & on behalf of the Swiss IBD Cohort Study Group (2014) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2014.02.014 · Cited by 23
Morón, J. M. V., Manrique, H. P., Machancoses, F. H., Lora, M. R., & Ruíz-Frutos, C. (2017) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2017.4542/2016 · Cited by 22
Network Medicine: A Mandatory Next Step for Inflammatory Bowel Disease
de Souza, H. S. P., & Fiocchi, C. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izx111 · Cited by 21
Ryu, D. G., Kim, H. W., Park, S. B., Kang, D. H., Choi, C. W., Kim, S. J., & Nam, H. S. (2019) · Medicine · doi:10.1097/md.0000000000017080 · Cited by 21 · cited 1×
“Other MH definitions used were the modified Baron Score (mBS = 0, mBS ≤ 1), the modified PICaSSO ≤ 3 [42], the Rachmilewitz Index (RI ≤ 1 [74], RI ≤ 2 [44], RI ≤ 4 [75]); the Simple Endoscopic Score for Ulcerative Colitis (SES-UC ≤ 3 [64]), and the Ulcerative Colitis Endoscopic Index of Severity (UCEIS = 0 [63], UCEIS…”
MethodHiraoka, S., Takashima, S., Inokuchi, T., Nakarai, A., Takahara, M., Harada, K., Seki, Y., Watanabe, K., Kato, J., & Okada, H. (2018) · Intestinal Research · doi:10.5217/ir.2018.00086 · Cited by 18
COVID-19 and Inflammatory Bowel Disease: Patient Knowledge and Perceptions in a Single Center Survey
Spagnuolo, R., Larussa, T., Iannelli, C., Cosco, C., Nisticò, E., Manduci, E., Bruno, A., Boccuto, L., Abenavoli, L., Luzza, F., et al. (2020) · Medicina · doi:10.3390/medicina56080407 · Cited by 17
Kim, E. S., Lee, H. S., Kim, S. K., Kim, E. Y., Jang, B. I., Kim, K. O., Yang, C. H., Lee, Y. J., & on behalf of the Crohn’s and Colitis Association in Daegu-Gyeongbuk (CCAiD) (2020) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2020.1714716 · Cited by 13
Moniuszko, A., Głuszek, S., & Rydzewska, G. (2017) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.4009 · Cited by 12
Yen, H., Chen, M.-W., Chang, Y., Huang, H.-Y., Hsu, T., & Chen, Y. (2020) · PeerJ · doi:10.7717/peerj.9537 · Cited by 12
Mine, S., Takeshima, F., Akazawa, Y., Matsushima, K., Minami, H., Yamaguchi, N., Ohnita, K., Isomoto, H., & Nakao, K. (2018) · Digestion · doi:10.1159/000484223 · Cited by 11
Karling, P., Lundgren, D. W., Eklöf, V., Palmqvist, R., & Hultdin, J. (2019) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2019.1622148 · Cited by 9
Infliximab levels and antibodies in IBD-related peripheral arthralgia
Levartovsky, A., Ungar, B., Yavzori, M., Picard, O., Fudim, E., Eliakim, R., Paul, S., Roblin, X., Ben‐Horin, S., & Kopylov, U. (2020) · International Journal of Colorectal Disease · doi:10.1007/s00384-020-03581-3 · Cited by 6 · cited 1×
“Successful control of intestinal inflammation may lead to improvement of extraintestinal manifestations of IBD, such as peripheral arthralgia [22], as well as relief in IBD-concomitant anxiety, depression, fatigue, and sleep disturbances [23].”
BackgroundVázquez-Morόn, J. M., Benítez-Rodríguez, B., Manrique, H. P., Machancoses, F. H., Rodríguez, J. L. R., Lora, M. R., & Ruíz-Frutos, C. (2017) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjx002.444 · Cited by 3
Gonzalez, H. A., Myers, S., Whitehead, E., Pattinson, A., Stamp, K., Turnbull, J., Fory, R., Featherstone, B., Wilkinson, A., Lisle, J., et al. (2020) · Clinical Medicine · doi:10.7861/clinmed.2020-0369 · Cited by 3
Cited by
British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025
Moran, G. W., Gordon, M., Sinopoulou, V., Radford, S. J., Darie, A.-M., Vuyyuru, S. K., Alrubaiy, L., Arebi, N., Blackwell, J., Butler, T. D., et al. (2025) · Gut · doi:10.1136/gutjnl-2024-334395 · Cited by 169
Inflammatory Bowel Disease and Neutrophil–Lymphocyte Ratio: A Systematic Scoping Review
Langley, B. O., Guedry, S. E., Goldenberg, J. Z., Hanes, D. A., Beardsley, J., & Ryan, J. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10184219 · Cited by 76
Kraszewski, S., Szczurek, W., Szymczak, J., Reguła, M., & Neubauer, K. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10204745 · Cited by 60
Self-citationŚlósarz, D., Poniewierka, E., Neubauer, K., & Kempiński, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10184044 · Cited by 33
“Furthermore, assessment of the effectiveness of treatment strategy requires endoscopy as other indices of mucosal healing (MH) are still unavailable [6].”
BackgroundSelf-citationFecal Calprotectin in Gastrointestinal Disease
Murray, J. L., Kok, K. B., & Ayling, R. M. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad051 · Cited by 40
Metadata
- Authors
- Bromke, M. A., Neubauer, K., Kempiński, R., & Krzystek-Korpacka, M.
- Affiliations
- Wroclaw Medical University (PL)
- Department of Biochemistry and Immunochemistry, Wroclaw Medical University, Chalubinskiego 10, 50-368 Wroclaw, Poland
- Corresponding author
- Bromke, Mariusz A.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2021-05-19
- Volume
- 10
- Issue
- 10
- Pages
- 2203
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC8161009
- OpenAlex
- W3161643431
- Cited by
- 39
- References
- 86
- Citations by year
- 2026: 6 · 2025: 3 · 2024: 14 · 2023: 6 · 2022: 4 · 2021: 6
- FWCI
- 1.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Gastroenterology › Microscopic Colitis
- Keywords
- fecal calprotectin, mucosal healing, inflammatory bowel disease, Crohn's disease, ulcerative colitis, non-invasive biomarkers, disease activity monitoring, diagnostic accuracy, diagnostic odds ratio, sensitivity and specificity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.